Why Neurocrine Biosciences Stock Sank Today
Both Guggenheim's Yatin Suneja and Wainwright's Andrew Fein were more modest in their Neurocrine price target cuts, with the former shaving $2 off his target to $163 per share and the latter reducing ...
Neurocrine initiated with a Hold at Deutsche Bank
Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Maximize Your Portfolio with Data Driven ...
FiercePharma1d
With Teva competition heating up, Neurocrine's tame Ingrezza forecast spooks investors
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Deutsche Bank sets Neurocrine stock with $138 price target
Deutsche Bank (ETR:DBKGn) began coverage on Neurocrine Biosciences (NASDAQ:NBIX) stock, assigning a Hold rating and setting a price target of $138. The bank's analyst noted that with a current market ...
Neurocrine stock target cut to $185 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein adjusted the price target for Neurocrine Biosciences (NASDAQ:NBIX) to $185 from the previous $190 while maintaining a Buy rating on the stock. This revision follows ...
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $163.00 at Guggenheim
Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a buy ...
Neurocrine price target lowered to $163 from $165 at Guggenheim
Guggenheim lowered the firm’s price target on Neurocrine (NBIX) to $163 from $165 and keeps a Buy rating on the shares after the company ...
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week
Shares of Neurocrine Biosciences Inc. plummeted 19 percent week-on-week to close Friday’s trading at $122.62 each as ...
Why Is Neurocrine Biosciences Stock Trading Lower On Friday?
Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...
Neurocrine Biosciences' (NASDAQ:NBIX) underlying earnings growth outpaced the notable return generated for shareholders over the past three years
It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43%, ...